RNN - Rexahn Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development10,089.14912,148.2267,015.901
Selling General and Administrative6,324.2366,115.216,253.328
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-16,413.385-18,263.436-13,269.229
Income from Continuing Operations
Total Other Income/Expenses Net7,419.134,089.996-5,046.2
Earnings Before Interest and Taxes-8,994.255-14,173.44-18,315.429
Interest Expense313.09211.116206.172
Income Before Tax-9,307.345-14,384.556-18,521.601
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-9,307.345-14,384.556-18,521.601
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-9,307.345-14,384.556-18,521.601
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-9,307.345-14,384.556-18,521.601